Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
| ▸ | PTGER3 | P43115 | 15/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CIT | O14578 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15053152 | 0.95 | BRAF (0.45) | CYP2D6CYP2C9BRAFPTGER3KDM4E | |
| SCHEMBL15053283 | 0.92 | MAPT (0.43) | CYP2D6CYP2C9BRAFPTGER3KDM4E | |
| SCHEMBL3705782 | 0.92 | CYP2D6 (0.51) | CYP2D6CYP2C9BRAFPTGER3KDM4E | |
| Hydrochloric Acid SCHEMBL3700562 | 0.91 | CYP2D6 (0.51) | CYP2D6CYP2C9BRAFPTGER3KDM4E | |
| SCHEMBL15053151 | 0.90 | BRAF (0.43) | CYP2D6CYP2C9BRAFCITBTK | |
| SCHEMBL15052968 | 0.90 | MEN1 (0.46) | CYP2D6CYP2C9BRAFKDM4EMAPT | |
| SCHEMBL15053328 | 0.89 | PTGER3 (0.43) | CYP2D6CYP2C9BRAFPTGER3KMT2A | |
| SCHEMBL15052787 | 0.89 | BRAF (0.39) | CYP2D6CYP2C9BRAFPTGER3KDM4E | |
| SCHEMBL15053504 | 0.89 | FGFR1 (0.46) | PTGER3KDM4EMAPTMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL15053371 | 0.89 | PTGER3 (0.43) | CYP2D6CYP2C9BRAFPTGER3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | claimed |
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK2, CDK1, CDK3 | CYP2D6 2955/4885CYP2C9 4082/4885BRAF 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.